Abstract
In children with SRS (patients), does initiation of recombinant GH therapy before 4 years of age (intervention) result in greater improvements in height and cardiometabolic outcomes (outcome) compared with initiation at 4 years or later (comparison)?

This publication has 10 references indexed in Scilit: